ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 168 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2020. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2020 | $9,862,000 | -24.1% | 379,326 | +8.6% | 0.01% | -42.9% |
Q3 2020 | $12,987,000 | -29.6% | 349,403 | -2.8% | 0.01% | -36.4% |
Q2 2020 | $18,444,000 | +83.7% | 359,464 | +12.9% | 0.02% | +29.4% |
Q1 2020 | $10,038,000 | -48.5% | 318,352 | -2.6% | 0.02% | -26.1% |
Q4 2019 | $19,487,000 | +93.2% | 326,798 | +18.8% | 0.02% | +53.3% |
Q3 2019 | $10,087,000 | -20.3% | 275,153 | +1.1% | 0.02% | +50.0% |
Q2 2019 | $12,658,000 | +15.2% | 272,097 | -0.6% | 0.01% | -33.3% |
Q1 2019 | $10,989,000 | -12.8% | 273,677 | -0.1% | 0.02% | +25.0% |
Q4 2018 | $12,607,000 | -17.2% | 274,061 | -20.2% | 0.01% | -40.0% |
Q3 2018 | $15,232,000 | +21.1% | 343,294 | +7.0% | 0.02% | +11.1% |
Q2 2018 | $12,573,000 | -41.0% | 320,815 | +8.9% | 0.02% | -47.1% |
Q1 2018 | $21,318,000 | +35.8% | 294,730 | +23.6% | 0.03% | +41.7% |
Q4 2017 | $15,695,000 | +64.9% | 238,384 | +25.5% | 0.02% | -20.0% |
Q3 2017 | $9,517,000 | – | 189,899 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |